Listen to this article on the DDW Podcast: Grant Cameron, Director at Clydeworth Consulting, examines the benefits of process intensification and highlights the steps which will improve process productivity, reduce environmental impact and decrease the cost of therapy manufacture while maintaining product quality. The move to continuous bioprocessing has been a major… Read More
Birmingham Biotech and the University of Birmingham have signed a licensing agreement to commercialise a novel anti-viral nasal spray that protects against Covid-19. The formulation was engineered by Professor Liam Grover, from the university’s Healthcare Technologies Institute, and a team of researchers who also collaborated on its testing. Covid-19… Read More
Clinical Ink, a clinical trial data and technology company, has acquired Digital Artefacts, a digital endpoint-based technology company. “The addition of Digital Artefacts now allows us to drive situational awareness because context matters. Data derived from Digital Artefacts can now increase the richness of our partners’ study… Read More
AstraZeneca’s Tagrisso (osimertinib) has been accepted for restricted use within NHS Scotland by the Scottish Medicines Consortium (SMC) for the treatment of early-stage lung cancer. Osimertinib will be used as monotherapy for the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have… Read More
Beximco Pharmaceuticals has launched a generic molnupiravir, an oral antiviral drug for symptomatic Covid-19 patients developed by Merck, Sharp & Dohme (MSD) and Ridgeback Biotherapeutics, following Emergency Use Authorisation by the Directorate General of Drug Administration (DGDA), the regulatory authority in Bangladesh. Molnupiravir is world’s first oral product to treat symptomatic Covid-19,… Read More
Doloromics has appointed Dr. Chris Flores as their new President and Chief Research and Development Officer. In this role, Dr. Flores will be responsible for leading the Doloromics portfolio of drug discovery and development programmes, two of which are scheduled to launch in early 2022, while building relationships with strategic partners and collaborators… Read More
Target class-specific libraries mean you need to screen less to identify high-quality antibodies. Aaron Sato, Chief Scientific Officer at Twist Bioscience, elaborates. Antibody developers are increasingly utilising antibody libraries to derive high-quality, drug-like biologics. However, only a few general-purpose libraries have been commercially available for drug discovery. As a result,… Read More
News round-up by DDW’s Megan Thomas for 8-12 November DDW’s Megan Thomas has selected five stories which highlight the collaborative work being done across the drug discovery industry. 1. SAGA Diagnostics and AstraZeneca enter assay development agreement SAGA Diagnostics, a cancer liquid… Read More
A study has found that some people are able to clear the Covid-19 virus quickly due to strong immune response from existing T-cells, which could lead to a new generation of vaccine development. In a study published in Nature, researchers found that individuals with potential exposure to… Read More
Enbiosis has made breakthrough in the treatment of irritable bowel syndrome (IBS), with 78% of the IBS patients who followed microbiome-based diets seeing symptoms improve dramatically. Dr. Tarkan Karakan, a gastroenterology specialist who helped conduct the study, said: “We believe this achievement represents a significant step towards demonstrating… Read More
OMass Therapeutics has shared its pipeline of five novel, differentiated small molecule drug programmes, targeting intractable or inadequately drugged membrane and complex-bound protein targets such as GPCRs (G-protein-coupled receptors), solute carriers and intracellular protein complexes. The company’s selected programmes focus on validated targets in immunology & rare disease indications with high unmet need. Read More
A free webinar, Sensitive signature peptide quantification using accurate mass spectrometry, was hosted by DDW on December 1, 2021, at 4PM GMT, 9AM PT; 12PM ET; 5PM CET. It was supported by SCIEX. Emerging advancements in protein biotherapeutics are driving the… Read More
Dunad Therapeutics has entered a strategic collaboration and license agreement with Novartis to generate orally bioavailable covalent and protein degrading small molecule drugs. Dunad will be responsible for programme execution up to lead optimisation, while Novartis will contribute target and ligand knowledge as well as access to assays… Read More
BridgeBio has collaborated with two new academic institutions, Columbia University and Mount Sinai (Icahn Mount Sinai), to translate research discoveries into potential therapies for patients with genetic diseases and genetically driven cancers. “Columbia University and Mount Sinai are known for bringing together some of the most talented scientists… Read More
Human cell coding company bit.bio has closed a Series B financing of $103 million to accelerate the clinical development of the company’s cell coding technology opti-oxTM, a breakthrough gene engineering approach that enables unlimited batches of any human cell to be manufactured consistently at scale through direct reprogramming of stem cells. … Read More
Antibiotic Research UK (ANTRUK) is funding seven new antibiotic research projects totalling £200,000, reportedly the largest sum it has ever awarded through its 2021 Small Research Grants / Career Development Awards scheme. The grants will fund essential academic research in both basic and applied sciences to help prevent another global pandemic,… Read More
